FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer

　　On June 24,2026,the U.S.Food and Drug Administration(FDA)granted approval for Pfizer Inc.’s CDK4/6 inhibitor,palbociclib(brand name:Ibrance),for a novel maintenance therapy indication.The regimen combines Ibrance with anti-HER2 targeted therapy—trastuzumab,with or without pertuzumab—and endocrine therapy.It is indicated for adult patients with hormone receptor(HR)-positive,human epidermal growth factor receptor 2(HER2)-positive locally advanced or metastatic breast cancer whose disease has stabilized following induction therapy.

　　HR-positive/HER2-positive breast cancer is driven by both hormonal signaling and HER2 amplification.While patients often achieve initial disease control after induction chemotherapy with taxanes plus anti-HER2 agents,traditional dual maintenance therapy(anti-HER2 plus endocrine therapy)frequently leads to resistance.By integrating CDK4/6 inhibition,the Ibrance-containing quadruplet regimen offers multi-pathway blockade to delay recurrence.This approval applies specifically to the maintenance phase for patients who have not progressed after induction treatment.

　　The approval is anchored by data from the Phase III PATINA trial(NCT02947685),which enrolled 518 eligible patients randomized 1:1.Results demonstrated that adding Ibrance to anti-HER2 therapy plus endocrine therapy reduced the risk of disease progression or death by 24%(Hazard Ratio=0.76;95%CI:0.59–0.97;one-sided p=0.0134).Median progression-free survival(PFS)estimates remain pending due to censoring,and overall survival(OS)data continue to mature.Nevertheless,the findings establish a significant improvement in progression-free survival with the addition of Ibrance.

　　Regarding safety,Ibrance carries Boxed Warnings for severe neutropenia and interstitial lung disease/pneumonitis,alongside warnings for embryo-fetal toxicity.Regular hematologic and pulmonary monitoring is required,and effective contraception is mandatory for those of reproductive potential.The recommended dosing schedule follows a 28-day cycle:Ibrance 125 mg orally once daily for 21 consecutive days,followed by a 7-day break.Trastuzumab,pertuzumab,and endocrine agents should be dosed per their respective prescribing information.Treatment continues until disease progression or unacceptable toxicity.As the first CDK4/6 inhibitor to demonstrate benefit in the maintenance setting for this patient population,Ibrance offers an oral,convenient option that redefines the global standard of care for advanced HR+/HER2+breast cancer.